NextCure (MUN:2US) - Aandelenkoers, Nieuws & Analyse

2US Overzicht aandelen

A clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Meer informatie

2US fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Risicoanalyse

Aandelen zijn zeer illiquide

De winst zal naar verwachting de komende drie jaar met gemiddeld 2.6% per jaar dalen.

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Heeft geen betekenisvolle marktkapitalisatie ( €45M )

+ 1 meer risico

NextCure, Inc. Concurrenten

4SC

DB:VSC

€51.9m

2invest

XTRA:2INV

€63.2m

Medigene

XTRA:MDG1

€20.6m

Heidelberg Pharma

XTRA:HPHA

€106.7m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor NextCure
Historische aandelenkoersen
Huidige aandelenkoers	US$1.37
52 Week Hoogtepunt	US$1.47
52 Week Laag	US$1.11
Bèta	0.67
11 maand verandering	0%
3 maanden verandering	8.57%
1 Jaar Verandering	n/a
33 jaar verandering	-77.99%
5 jaar verandering	n/a
Verandering sinds IPO	-92.59%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	2US	DE Biotechs	DE Markt
7D	0%	0.8%	0.8%
1Y	n/a	-18.3%	8.6%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe 2US presteerde ten opzichte van de German Biotechs.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe 2US presteerde ten opzichte van de German markt.

Prijsvolatiliteit

Is 2US's price volatile compared to industry and market?
2US volatility
2US Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: 2US heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van 2US in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2015	82	Michael Richman	www.nextcure.com

NextCure, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van NextCure zich tot de beurswaarde?
2US fundamentele statistieken
Marktkapitalisatie	€41.33m
Inkomsten(TTM)	-€58.86m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-0.7x

Koers/Winstverhouding

Is 2US overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
2US resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$63.73m
Inkomsten	-US$63.73m

Laatst gerapporteerde inkomsten

Mar 31, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-2.28
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde 2US op de lange termijn?

Bekijk historische prestaties en vergelijking

2US Overzicht aandelen

Risicoanalyse

NextCure, Inc. Concurrenten

DB:VSC

€51.9m

XTRA:2INV

€63.2m

XTRA:MDG1

€20.6m

XTRA:HPHA

€106.7m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

NextCure, Inc. Announces the Presentation of Preclinical Data Demonstrating That Treatment with Nc605, A Novel Anti-Siglec-15 (S15) Antibody

NextCure, Inc. Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo At Society for Immunotherapy of Cancer Annual Meeting

NextCure, Inc. Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

New major risk - Revenue and earnings growth

NextCure, Inc., Annual General Meeting, Jun 20, 2024

NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024

Recent updates

NextCure, Inc. Announces the Presentation of Preclinical Data Demonstrating That Treatment with Nc605, A Novel Anti-Siglec-15 (S15) Antibody

NextCure, Inc. Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo At Society for Immunotherapy of Cancer Annual Meeting

NextCure, Inc. Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

New major risk - Revenue and earnings growth

NextCure, Inc., Annual General Meeting, Jun 20, 2024

NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024

NextCure, Inc. Appoints Rakesh Dixit to Scientific Advisory Board

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

Nextcure, Inc. Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury

Nextcure, Inc. Provides Year-End Clinical Pipeline Updates

NextCure, Inc. Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML

NextCure, Inc. Announces Presentation of New Preclinical Data Demonstrate Treatment with NC605

NextCure, Inc. Presents Preclinical Data on Nc181, A Novel Therapeutic Candidate Targeting Apoe4, for the Treatment of Alzheimer's Disease

NextCure, Inc. Announces Resignation of Garry A. Nicholson as from the Board of Directors

NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting

NextCure, Inc. Appoints Lisa M. Coussens to Scientific Advisory Board

NextCure, Inc. Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors

NextCure, Inc. Presents NC410 Data at the Extracellular Matrix Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM

Nextcure, Inc. Appoints Dr. Segal to Its Scientific Advisory Board

NextCure, Inc., Annual General Meeting, Jun 23, 2022

NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation

High number of new directors

High number of new directors

NextCure, Inc. and Collaborators Provide Data on Targets in Development at American Society of Hematology Annual Meeting

High number of new directors

Independent Director Xiaoxing Xu has left the company

NextCure, Inc.(NasdaqGS:NXTC) dropped from Russell 2500 Growth Index

Nextcure and Collaborators Publish Preclinical Data on Novel Immunomedicine Nc410

Independent Director has left the company

Full year 2020 earnings released: US$1.33 loss per share (vs US$2.15 loss in FY 2019)

Revenue misses expectations

NextCure, Inc. Announces Resignation of Briggs Morrison from the Board of Directors, Effective April 1, 2021

The Schall Law Firm Announces the Filing of A Class Action Lawsuit Against Nextcure, Inc

New 90-day high: €10.30

NextCure, Inc. Announces the Appointment of Han Myint as Chief Medical Officer

NextCure, Inc. Provides Updates on NC318 Clinical Program

New 90-day high: €10.10

Rosen Reminds Nextcure, Inc. Investors of Important November 20 Deadline in Securities Class Action

Revenue in line with expectations

Bernstein Liebhard Reminds Investors of the Deadline to File Lead Plaintiff Motion in Securities Class Action Lawsuit Against Nextcure Inc

Block & Leviton LLP Reminds Investors of Nextcure, Inc. for Violations of the Federal Securities Laws

New 90-day low: €7.25

Nextcure, Inc. Announces Resignation of Kevin N. Heller from Chief Medical Officer

Scott+Scott Attorneys At Law LLP Files Securities Class Action Against NextCure Inc

New 90-day low - €7.65

First half earnings released

NextCure, Inc.(NasdaqGS:NXTC) dropped from Russell Microcap Value Index

NextCure, Inc.(NasdaqGS:NXTC) dropped from Russell Microcap Index

NextCure, Inc.(NasdaqGS:NXTC) dropped from S&P Biotechnology Select Industry Index

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

NextCure, Inc. Samenvatting

0.0x

-0.7x

Inkomsten en omzet